Arrowhead Pharmaceuticals, Inc.
ARWR
$83.33
-$1.78-2.09%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 75.25M | 73.74M | 264.03M | 256.47M | 27.77M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 75.25M | 73.74M | 264.03M | 256.47M | 27.77M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 75.25M | 73.74M | 264.03M | 256.47M | 27.77M |
| SG&A Expenses | 54.14M | 49.34M | 49.70M | 31.29M | 37.41M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 245.35M | 215.00M | 223.22M | 212.37M | 193.32M |
| Operating Income | -170.09M | -141.26M | 40.81M | 44.11M | -165.55M |
| Income Before Tax | -178.91M | -137.57M | 28.27M | 36.12M | -179.09M |
| Income Tax Expenses | 11.00K | 7.00K | 29.00K | 20.00M | -437.00K |
| Earnings from Continuing Operations | -178.92M | -137.57M | 28.24M | 16.12M | -178.65M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -15.36M | 4.84M | 2.57M | -39.87M | 3.41M |
| Net Income | -194.28M | -132.73M | 30.81M | -23.75M | -175.24M |
| EBIT | -170.09M | -141.26M | 40.81M | 44.11M | -165.55M |
| EBITDA | -163.43M | -134.89M | 47.20M | 50.49M | -159.33M |
| EPS Basic | -1.36 | -0.93 | 0.22 | -0.17 | -1.26 |
| Normalized Basic EPS | -0.89 | -0.65 | 0.15 | -0.13 | -0.78 |
| EPS Diluted | -1.36 | -0.93 | 0.22 | -0.17 | -1.26 |
| Normalized Diluted EPS | -0.89 | -0.65 | 0.14 | -0.13 | -0.78 |
| Average Basic Shares Outstanding | 143.38M | 142.42M | 137.04M | 137.88M | 139.04M |
| Average Diluted Shares Outstanding | 143.38M | 142.42M | 140.71M | 137.88M | 139.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |